{"content":"<li class=\"n-box-item date-title\" data-end=\"1535428799\" data-start=\"1535342400\" data-txt=\"Monday, December 23, 2019\">Monday, August 27, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3385989\" data-ts=\"1535423739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BILI\" target=\"_blank\">BILI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385989-bilibili-beats-rmb0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bilibili beats by RMB0.06, beats on revenue</a></h4><ul><li>Bilibili (NASDAQ:<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili Inc.'>BILI</a>): Q2 Non-GAAP EPS of -RMB0.07 beats by RMB0.06; GAAP EPS of -RMB0.26 misses by RMB0.07.</li><li>Revenue of $155.1M (76% Y/Y)&nbsp;<font color='green'>beats by $6.57M</font>.</li><li>Shares <font color='green'>+7.5%</font> AH.</li><li><a href=\"https://seekingalpha.com/pr/17254470-bilibili-inc-announces-second-quarter-2018-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3385989\" data-linked=\"Bilibili beats by RMB0.06, beats on revenue\" data-tweet=\"$BILI - Bilibili beats by RMB0.06, beats on revenue https://seekingalpha.com/news/3385989-bilibili-beats-rmb0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3385989-bilibili-beats-rmb0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385988\" data-ts=\"1535420020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAHC\" target=\"_blank\">PAHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385988-phibro-animal-health-fq4-top-line-up-9-earnings-up-44-cash-flow-down-26-shares-down-4-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phibro Animal Health FQ4 top line up 9%; earnings up 44%; cash flow down 26%; shares down 4% after hours</a></h4><ul><li>Phibro Animal Health (NASDAQ:<a href='https://seekingalpha.com/symbol/PAHC' title='Phibro Animal Health Corporation'>PAHC</a>) <a href=\"https://seekingalpha.com/pr/17254439-phibro-animal-health-corporation-reports-fourth-quarter-fiscal-year-results-presents\" target=\"_blank\">fiscal Q4 results</a> ($M): Net sales: 211.8 (+8.7%).</li><li>Net income: 22.1 (+43.5%); EPS: 0.55 (+44.7%); non-GAAP EPS: 0.46 (+17.9%); non-GAAP EBITDA: 33.0 (+12.2%).</li><li>Cash flow ops: 10.1 (-25.7%).</li><li><strong>Fiscal 2019 guidance</strong>: Sales: $850M - 875M; net income: $64M - 66M; EPS: $1.57 - 1.62; non-GAAP EPS: $1.72 - 1.77; non-GAAP EBITDA: $129M - 131M.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385988\" data-linked=\"Phibro Animal Health FQ4 top line up 9%; earnings up 44%; cash flow down 26%; shares down 4% after hours\" data-tweet=\"$PAHC - Phibro Animal Health FQ4 top line up 9%; earnings up 44%; cash flow down 26%; shares down 4% after hours https://seekingalpha.com/news/3385988-phibro-animal-health-fq4-top-line-up-9-earnings-up-44-cash-flow-down-26-shares-down-4-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3385988-phibro-animal-health-fq4-top-line-up-9-earnings-up-44-cash-flow-down-26-shares-down-4-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385984\" data-ts=\"1535406524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385984-yahoo-fitbit-sitting-on-150b-hours-of-heart-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yahoo: Fitbit sitting on 150B hours of heart data</a></h4><ul>   <li>Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) closed the day <font color='green'>up 3.3%</font> after a <a href=\"https://finance.yahoo.com/news/exclusive-fitbits-150-billion-hours-heart-data-reveals-secrets-human-health-133124215.html\" target=\"_blank\">Yahoo Finance report</a> notes the company has logged 150B hours worth of heart-rate data from around the world, the biggest such set ever collected.</li>    <li>Those heartbeats are paired with people's ages, sexes, locations, heights/weights, activity levels and sleep patterns, the report says.</li>    <li>The data is anonymized, David Pogue notes, and there is some bias in the fact that it all comes from people who are affluent enough to own Fitbit devices.</li>    <li>Some key information comes from resting heart rate, an informative metric that looks to be a strong predictor of early death and has links to diabetes as well.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385984\" data-linked=\"Yahoo: Fitbit sitting on 150B hours of heart data\" data-tweet=\"$FIT - Yahoo: Fitbit sitting on 150B hours of heart data https://seekingalpha.com/news/3385984-yahoo-fitbit-sitting-on-150b-hours-of-heart-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3385984-yahoo-fitbit-sitting-on-150b-hours-of-heart-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385982\" data-ts=\"1535405931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385982-after-hours-gainers-losers-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (08/27/2018)</a></h4><ul>     <li><strong>Top Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='green'>+112.3%</font>. <a href='https://seekingalpha.com/symbol/BRKS' title='Brooks Automation, Inc.'>BRKS</a> <font color='green'>+15.7%</font>. <a href='https://seekingalpha.com/symbol/HEI' title='HEICO Corporation'>HEI</a> <font color='green'>+5.8%</font>. <a href='https://seekingalpha.com/symbol/LSCC' title='Lattice Semiconductor Corporation'>LSCC</a> <font color='green'>+5.4%</font>. <a href='https://seekingalpha.com/symbol/LEVB' title='Level Brands, Inc.'>LEVB</a> <font color='green'>+4.1%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/WMGI' title='Wright Medical Group, Inc.'>WMGI</a>&nbsp;<font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a>&nbsp;<font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a>&nbsp;<font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/BPY' title='Brookfield Property Partners L.P.'>BPY</a>&nbsp;<font color='red'>-1.3%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>&nbsp;<font color='red'>-1.0%.</font></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3385982\" data-linked=\"After Hours Gainers / Losers (08/27/2018)\" data-tweet=\"$AFMD $AFMD $BRKS - After Hours Gainers / Losers (08/27/2018) https://seekingalpha.com/news/3385982-after-hours-gainers-losers-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385982-after-hours-gainers-losers-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385978\" data-ts=\"1535404351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEI\" target=\"_blank\">HEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385978-heicoplus-5_5-after-record-sales-and-profits-and-boosts-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heico +5.5% after record sales and profits, and boosts guidance</a></h4><ul>   <li>Aerospace/defense firm Heico (<a href='https://seekingalpha.com/symbol/HEI' title='HEICO Corporation'>HEI</a>) is <font color='green'>up 5.5%</font> after hours following <a href=\"https://seekingalpha.com/news/3385958-heico-beats-revenue\" target=\"_blank\">Q3 results</a> where it topped high estimates and raised guidance on sales growth.</li>    <li>The company hit records in net sales ($465.8M, up 19%), operating income ($101.4M, up 33%) and net income ($67.1M, up 47%).</li>    <li>Operating margin improved to 21.8% from a year-ago 19.4%.</li>    <li>Cash flow from operations was $204.7M (up 14%) for the first nine months. For the quarter, it rose 34% to $109.7M.</li>    <li>Net sales by segment: Flight Support Group, $807.7M (up 13.6%); Electronic Technologies Group, $510.8M (up 26.1%).</li>    <li>For the full year, it's guiding to net sales growth of 20-21% (up from a previous forecast of 18-20%) and for the Electronic Technologies Group's operating margin to hit 28.5-29%, up from 28-29%.</li>    <li>Conference call to come tomorrow at 9 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17254373-heico-corporation-reports-record-net-sales-operating-income-net-income-third-quarter-fiscal\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3385978\" data-linked=\"Heico +5.5% after record sales and profits, and boosts guidance\" data-tweet=\"$HEI $HEI.A - Heico +5.5% after record sales and profits, and boosts guidance https://seekingalpha.com/news/3385978-heicoplus-5_5-after-record-sales-and-profits-and-boosts-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3385978-heicoplus-5_5-after-record-sales-and-profits-and-boosts-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385969\" data-ts=\"1535402682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385969-affimed-teams-up-genentech-to-develop-cancer-therapies-in-potential-multi-billion-dollar-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affimed teams up with Genentech to develop cancer therapies in potential multi-billion dollar deal; shares up 113% after hours</a></h4><ul><li>Affimed N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a>) inks a collaboration <a href=\"https://seekingalpha.com/pr/17254367-affimed-announces-collaboration-genentech-develop-novel-nk-cell-engager-based\" target=\"_blank\">agreement </a>with Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) unit Genentech aimed at developing novel NK cell engager-based therapies for a range of cancers leveraging Affimed's proprietary Redirected Optimized Cell Killing &#40;ROCK&#41; platform.</li><li>Under the terms of the agreement, Affimed will receive $96M upfront, up to $5B in milestones and royalties on net sales.</li><li>Shares are up&nbsp;<font color='green'>113%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385969\" data-linked=\"Affimed teams up with Genentech to develop cancer therapies in potential multi-billion dollar deal; shares up 113% after hours\" data-tweet=\"$AFMD $AFMD $RHHBY - Affimed teams up with Genentech to develop cancer therapies in potential multi-billion dollar deal; shares up 113% after hours https://seekingalpha.com/news/3385969-affimed-teams-up-genentech-to-develop-cancer-therapies-in-potential-multi-billion-dollar-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3385969-affimed-teams-up-genentech-to-develop-cancer-therapies-in-potential-multi-billion-dollar-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385966\" data-ts=\"1535402198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385966-fda-rejects-ionis-pharma-and-akceas-volanesorsen-for-fcs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Ionis Pharma and Akcea&#39;s volanesorsen for FCS</a></h4><ul><li>Ionis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) and affiliate Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a>) are set for significant down moves on the heels of a <a href=\"https://seekingalpha.com/pr/17254400-akcea-ionis-receive-complete-response-letter-waylivra-fda\" target=\"_blank\">CRL from the FDA</a> regarding the marketing application seeking approval for WAYLIVRA (volanesorsen) for the treatment of familial chylomicronemia syndrome &#40;FCS&#41;.</li><li>An FDA advisory committee voted 12-8 in favor of approval in May.</li><li>Akcea chief Paula Soteropoulos says, &ldquo;We are extremely disappointed with the FDA&rsquo;s decision. FCS is an ultra-rare and debilitating disease. Our disappointment extends to the patient and physician community who currently do not have a treatment available to them. We continue to feel strongly that WAYLIVRA demonstrates a favorable benefit/risk profile in people with FCS as was reflected in the positive outcome from our Advisory Committee hearing in May. We will continue to work with the FDA to confirm the path forward.\"</li><li>Shares, currently halted, will resume trading at 5:00 pm ET for both companies.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355794-ionis-akcea-premarket-ad-com-vote\" target=\"_blank\">Ionis and Akcea up premarket after Ad Com vote</a> (May 11)</li><li><strong>Update</strong>: IONS is down&nbsp;<font color='red'>12%</font>&nbsp;premarket while AKCA is down&nbsp;<font color='red'>28%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385966\" data-linked=\"FDA rejects Ionis Pharma and Akcea&#39;s volanesorsen for FCS\" data-tweet=\"$IONS $IONS $AKCA - FDA rejects Ionis Pharma and Akcea&#39;s volanesorsen for FCS https://seekingalpha.com/news/3385966-fda-rejects-ionis-pharma-and-akceas-volanesorsen-for-fcs?source=tweet\" data-url=\"https://seekingalpha.com/news/3385966-fda-rejects-ionis-pharma-and-akceas-volanesorsen-for-fcs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385965\" data-ts=\"1535401780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385965-ionis-and-akcea-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis and Akcea shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Ionis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) and Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a>) pending the release of news, most likely related to the pending FDA decision on volanesorsen for familial chylomicronemia syndrome.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385965\" data-linked=\"Ionis and Akcea shares halted pending news\" data-tweet=\"$IONS $IONS $AKCA - Ionis and Akcea shares halted pending news https://seekingalpha.com/news/3385965-ionis-and-akcea-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3385965-ionis-and-akcea-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385962\" data-ts=\"1535401498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTPH\" target=\"_blank\">TTPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385962-fda-oks-tetraphase-pharmas-eravacycline-for-ciai\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Tetraphase Pharma&#39;s eravacycline for cIAI</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17254387-tetraphase-pharmaceuticals-announces-fda-approval-xerava-eravacycline-complicated-intra\" target=\"_blank\">approved </a>Tetraphase Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals'>TTPH</a>) XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI) in patients at least 18 years old.</li><li>Management will host a conference call at 4:30 pm ET to discuss the approval.</li><li>Shares, currently halted, will resume trading at 3:40 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385962\" data-linked=\"FDA OKs Tetraphase Pharma&#39;s eravacycline for cIAI\" data-tweet=\"$TTPH - FDA OKs Tetraphase Pharma&#39;s eravacycline for cIAI https://seekingalpha.com/news/3385962-fda-oks-tetraphase-pharmas-eravacycline-for-ciai?source=tweet\" data-url=\"https://seekingalpha.com/news/3385962-fda-oks-tetraphase-pharmas-eravacycline-for-ciai\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385961\" data-ts=\"1535401467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385961-seven-stars-cloud-clarifies-registration-filing-shares-continue-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Cloud clarifies registration filing; shares continue down</a></h4><ul>    <li>Seven Stars Cloud (NASDAQ:<a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>) has issued a <a href=\"https://seekingalpha.com/pr/17254326-clarification-recent-news-regarding-company-filing\" target=\"_blank\">clarification</a> about confusion over new financing.</li>    <li>\"Contrary to earlier news this morning, SSC is not issuing any new financing at this time,\" the company says, noting that Friday's <a href=\"https://seekingalpha.com/filing/4149181\" target=\"_blank\">S-1/A filing</a> is just an amendment to the <a href=\"https://seekingalpha.com/filing/3983336\" target=\"_blank\">S-1 filed on April 20</a>.</li>    <li>The new filing isn't indicative of new share issuance that would be dilutive, it says, just a registration for currently outstanding shares.</li>    <li>\"Further, as previously disclosed over the past few months, SSC's management team feels that the Company is well capitalized to continue to execute and deliver on its strategy,\" SSC says.</li>    <li>Shares <font color='red'>slid 8.7%</font> during the market day on Nasdaq; they're <font color='red'>off 1.2%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385961\" data-linked=\"Seven Stars Cloud clarifies registration filing; shares continue down\" data-tweet=\"$SSC-OLD - Seven Stars Cloud clarifies registration filing; shares continue down https://seekingalpha.com/news/3385961-seven-stars-cloud-clarifies-registration-filing-shares-continue-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3385961-seven-stars-cloud-clarifies-registration-filing-shares-continue-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385958\" data-ts=\"1535401204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEI\" target=\"_blank\">HEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385958-heico-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HEICO beats on revenue</a></h4><ul><li>HEICO (NYSE:<a href='https://seekingalpha.com/symbol/HEI' title='HEICO Corporation'>HEI</a>): Q3 GAAP EPS of $0.49 beats by $0.04.</li><li>Revenue of $465.82M (+19.0% Y/Y) <font color='green'>beats by $26.04M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17254373-heico-corporation-reports-record-net-sales-operating-income-net-income-third-quarter-fiscal\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3385958\" data-linked=\"HEICO beats on revenue\" data-tweet=\"$HEI $HEI.A - HEICO beats on revenue https://seekingalpha.com/news/3385958-heico-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3385958-heico-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385959\" data-ts=\"1535401204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ILMN\" target=\"_blank\">ILMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385959-illumina-ngs-system-okd-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Illumina NGS system OK&#39;d in China</a></h4><ul><li>The China National Drug Administration has <a href=\"https://seekingalpha.com/pr/17254349-illumina-receives-approval-miseq-dx-system-china\" target=\"_blank\">approved</a> Illumina's (NASDAQ:<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a>) next-gen sequencing system, MiSeq Dx, the first such approval there.</li><li>The product is also approved for sale in the U.S., EU, Canada, Argentina, Australia, South Korea, Singapore, Thailand and the Philippines.</li><li>Shares are up a fraction after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385959\" data-linked=\"Illumina NGS system OK&#39;d in China\" data-tweet=\"$ILMN - Illumina NGS system OK&#39;d in China https://seekingalpha.com/news/3385959-illumina-ngs-system-okd-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3385959-illumina-ngs-system-okd-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385957\" data-ts=\"1535401152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LSCC\" target=\"_blank\">LSCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385957-lattice-names-amds-anderson-new-ceo-sharesplus-6_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lattice names AMD&#39;s Anderson as new CEO; shares +6.4%</a></h4><ul>   <li>Lattice Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/LSCC' title='Lattice Semiconductor Corporation'>LSCC</a>) has named Jim Anderson <a href=\"https://seekingalpha.com/pr/17254335-lattice-semiconductor-appoints-jim-anderson-ceo\" target=\"_blank\">president and chief executive officer</a>.</li>    <li>Shares have <font color='green'>jumped 6.4%</font> after hours.</li>    <li>That move is effective Sept. 4. Anderson also joins the board of directors.</li>    <li>He comes from Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>), where he was GM and senior VP of the Computing and Graphics business group. <a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> is <font color='red'>0.6% lower</font> after hours.</li>    <li>Glen Hawk, Lattice's chief operating officer, has been serving as interim CEO; he'll work as special advisor to the CEO through Oct. 31 before leaving Lattice for other opportunities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385957\" data-linked=\"Lattice names AMD&#39;s Anderson as new CEO; shares +6.4%\" data-tweet=\"$LSCC $LSCC $AMD - Lattice names AMD&#39;s Anderson as new CEO; shares +6.4% https://seekingalpha.com/news/3385957-lattice-names-amds-anderson-new-ceo-sharesplus-6_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3385957-lattice-names-amds-anderson-new-ceo-sharesplus-6_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385954\" data-ts=\"1535400942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMGI\" target=\"_blank\">WMGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385954-wright-medical-group-launches-440m-stock-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wright Medical Group launches $440M stock offering; shares down 3% after hours</a></h4><ul><li>Wright Medical Group N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/WMGI' title='Wright Medical Group, Inc.'>WMGI</a>) is down&nbsp;<font color='red'>3%</font>&nbsp;after hours on the heels of its announced <a href=\"https://seekingalpha.com/pr/17254340-wright-medical-group-n-v-announces-proposed-public-offering-ordinary-shares\" target=\"_blank\">public offering</a> of $440M of its ordinary shares. Price, volume and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385954\" data-linked=\"Wright Medical Group launches $440M stock offering; shares down 3% after hours\" data-tweet=\"$WMGI - Wright Medical Group launches $440M stock offering; shares down 3% after hours https://seekingalpha.com/news/3385954-wright-medical-group-launches-440m-stock-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3385954-wright-medical-group-launches-440m-stock-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385953\" data-ts=\"1535400754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGNX\" target=\"_blank\">RGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385953-ultragenyxs-mepsevii-okd-in-europe-for-mps-vii\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultragenyx&#39;s Mepsevii OK&#39;d in Europe for MPS VII</a></h4><ul><li>As expected, the European Commission approves Ultragenyx's Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of <a href=\"https://rarediseases.info.nih.gov/diseases/7096/mucopolysaccharidosis-type-vii\" target=\"_blank\">mucopolysaccharidosis VII</a> (MPS VII) of Sly syndrome, a rare inherited lysosomal storage disorder.</li><li>The advisory group CHMP adopted a positive opinion backing approval two months ago.</li><li>MPS-related tickers (different types): <a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>, <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>, <a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>, <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>, <a href='https://seekingalpha.com/symbol/BIOVF' title='Swedish Orphan Biovitrum AB'>OTCPK:BIOVF</a>, <a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3385953\" data-linked=\"Ultragenyx&#39;s Mepsevii OK&#39;d in Europe for MPS VII\" data-tweet=\"$RGNX $RGNX $SGMO - Ultragenyx&#39;s Mepsevii OK&#39;d in Europe for MPS VII https://seekingalpha.com/news/3385953-ultragenyxs-mepsevii-okd-in-europe-for-mps-vii?source=tweet\" data-url=\"https://seekingalpha.com/news/3385953-ultragenyxs-mepsevii-okd-in-europe-for-mps-vii\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385951\" data-ts=\"1535400694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITK\" target=\"_blank\">MITK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385951-mitek-systems-ceo-cfo-plan-departures-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitek Systems CEO, CFO plan departures (updated)</a></h4><ul>   <li>Mitek Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a>) says its CEO, Jim DeBello, is <a href=\"https://seekingalpha.com/pr/17254354-mitek-announces-executive-transitions\" target=\"_blank\">transitioning out of that role</a> with a departure effective Jan. 1, 2019.</li>    <li>Lead independent director Bruce Hansen is immediately taking the role of chairman.</li>    <li>DeBello has been a director for 23 years, CEO for 15 years and chairman for two years.</li>    <li>The company says in an unrelated development, Chief Financial Officer Jeff Davison is exiting at the end of November to join a firm near his home in Bozeman, Mont. He informed the company his \"voluntary departure is for personal and family reasons and not due to any disagreement with the Company on any matter related to the Company&rsquo;s operations, policies or practices.\"</li>    <li>The company says it will engage a search firm to find a new CEO and CFO.</li>    <li>It also reaffirmed full-year revenue guidance of $62M-$63M and expects non-GAAP profit margin of 15-16%.</li>    <li>Shares are halted and will resume quotes at 4:30 p.m. and resume trading at 4:35 p.m. They <font color='red'>fell 5.1%</font>&nbsp;today.</li><li><strong>Updated 4:39 p.m.:</strong> Shares have resumed trading and are <font color='red'>down 10.6%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385951\" data-linked=\"Mitek Systems CEO, CFO plan departures (updated)\" data-tweet=\"$MITK - Mitek Systems CEO, CFO plan departures (updated) https://seekingalpha.com/news/3385951-mitek-systems-ceo-cfo-plan-departures-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3385951-mitek-systems-ceo-cfo-plan-departures-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385948\" data-ts=\"1535400264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITK\" target=\"_blank\">MITK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385948-mitek-halted-for-news-shares-closeminus-5_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitek halted for news; shares close -5.1%</a></h4><ul>    <li>Shares in Mitek Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems Inc.'>MITK</a>) have been halted at the close for news pending.</li>    <li>A decline in the shares got a bit steeper in the afternoon before they ended up <font color='red'>down 5.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385948\" data-linked=\"Mitek halted for news; shares close -5.1%\" data-tweet=\"$MITK - Mitek halted for news; shares close -5.1% https://seekingalpha.com/news/3385948-mitek-halted-for-news-shares-closeminus-5_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3385948-mitek-halted-for-news-shares-closeminus-5_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385947\" data-ts=\"1535400108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385947-petrobras-looks-to-restart-replan-activity-wednesday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras looks to restart Replan activity by Wednesday</a></h4><ul>   <li>Petrobras (<a href=\"http://seekingalpha.com/symbol/PBR\" target=\"_blank\">PBR</a> <font color='green'>+1.8%</font>) is looking to resume activities at Brazil's biggest refinery by Wednesday, the oil workers' union says.</li>    <li>A fire <a href=\"https://seekingalpha.com/news/3384229-petrobras-says-fire-controlled-biggest-refinery-fuel-supplies-unaffected\" target=\"_blank\">shut the entirety of Replan</a> Aug. 20, though the company did not expect a disruption to fuel supplies.</li>    <li>The company held off plans to restart the refinery, which runs 434,000 bpd, after an order from regulator ANP, but ANP is expecting paperwork allowing a restart of refinery units not affected by the fire.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385947\" data-linked=\"Petrobras looks to restart Replan activity by Wednesday\" data-tweet=\"$PBR - Petrobras looks to restart Replan activity by Wednesday https://seekingalpha.com/news/3385947-petrobras-looks-to-restart-replan-activity-wednesday?source=tweet\" data-url=\"https://seekingalpha.com/news/3385947-petrobras-looks-to-restart-replan-activity-wednesday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385944\" data-ts=\"1535399940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GS\" target=\"_blank\">GS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385944-banks-gain-u-s-mexico-reach-deal-economy-seems-on-firm-footing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks gain as U.S., Mexico reach deal, economy seems on firm footing</a></h4><ul><li>Big bank stocks climb strongly as the U.S. and Mexico announce a trade agreement, and the U.S. economy appears on solid footing.</li><li>On Friday, Federal Reserve Chairman Jerome Powell reaffirmed that the Fed plans to continue a gradual normalization of monetary policy, giving some reassurance that the Fed won't move too fast on raising rates.</li><li>The trade agreement provides some relief to the recent escalation of trade tensions. In addition to the Mexico deal, President Trump says the U.S. will immediately start talks with Canada, part of his effort to replace the North American Free Trade Agreement that went into effect in 1994.</li><li>Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='green'>+3.1%</font>) and Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='green'>+3.7%</font>) lead the gains, followed by Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='green'>+2.5%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='green'>+1.8%</font>), Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='green'>+1.4%</font>), and Wells Fargo.</li><li>The last week of August, though, typically feature thin-trading volumes, since it's one of the most popular weeks of the year for vacation. Those thin volumes can exaggerate swings in the market.</li><li>Regional banks are also faring well: PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='green'>+1.9%</font>), SunTrust Banks (<a href='https://seekingalpha.com/symbol/STI' title='SunTrust Banks, Inc.'>STI</a> <font color='green'>+1.3%</font>), and Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='green'>+1%</font>) show the strongest gains.</li><li>It's not just U.S. banks doing well. Brazil's big banks are all advancing -- Itau Unibanco Holdings (<a href='https://seekingalpha.com/symbol/ITUB' title='Itau Unibanco Holding S.A.'>ITUB</a> <font color='green'>+3.3%</font>), Banco Santander Brasil (<a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a> <font color='green'>+2.1%</font>), Banco Bradesco (<a href='https://seekingalpha.com/symbol/BBD' title='Banco Bradesco, S.A.'>BBD</a> <font color='green'>+2.5%</font>).</li><li>Other international banks advancing are: Germany's Deutsche Bank (<a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a> <font color='green'>+3%</font>), India's ICICI Bank (<a href='https://seekingalpha.com/symbol/IBN' title='ICICI Bank Ltd.'>IBN</a> <font color='green'>+3%</font>), U.K.'s Barclays (<a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a> <font color='green'>+1.8%</font>), Argentina's Banco Bilbao Vizcaya Argentina (<a href='https://seekingalpha.com/symbol/BBVA' title='Banco Bilbao Vizcaya Argentaria, S.A.'>BBVA</a> <font color='green'>+1.5%</font>), and Canada's Toronto-Dominion Bank (<a href='https://seekingalpha.com/symbol/TD' title='Toronto-Dominion Bank'>TD</a> <font color='green'>+1%</font>) and Bank of Nova Scotia (<a href='https://seekingalpha.com/symbol/BNS' title='The Bank of Nova Scotia'>BNS</a> <font color='green'>+1.3%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385886-stock-markets-record-highs-u-s-mexico-reach-trade-deal\" target=\"_blank\">Stock markets at record highs after U.S. and Mexico reach trade deal</a> (Aug. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385944\" data-linked=\"Banks gain as U.S., Mexico reach deal, economy seems on firm footing\" data-tweet=\"$GS $GS $MS - Banks gain as U.S., Mexico reach deal, economy seems on firm footing https://seekingalpha.com/news/3385944-banks-gain-u-s-mexico-reach-deal-economy-seems-on-firm-footing?source=tweet\" data-url=\"https://seekingalpha.com/news/3385944-banks-gain-u-s-mexico-reach-deal-economy-seems-on-firm-footing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385942\" data-ts=\"1535399550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTPH\" target=\"_blank\">TTPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385942-tetraphase-pharma-halted-pending-news-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tetraphase Pharma halted pending news; up 10%</a></h4><ul><li>Nasdaq has suspended trading in Tetraphase Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals'>TTPH</a> <font color='green'>+10.1%</font>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385942\" data-linked=\"Tetraphase Pharma halted pending news; up 10%\" data-tweet=\"$TTPH - Tetraphase Pharma halted pending news; up 10% https://seekingalpha.com/news/3385942-tetraphase-pharma-halted-pending-news-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3385942-tetraphase-pharma-halted-pending-news-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385936\" data-ts=\"1535398232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REPH\" target=\"_blank\">REPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385936-specialty-pharmacy-operators-in-red\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Specialty pharmacy operators in the red</a></h4><ul><li>Specialty pharmacy services providers Recro Pharma (<a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma Inc'>REPH</a> <font color='red'>-5.3%</font>) and Diplomat Pharmacy (<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy'>DPLO</a> <font color='red'>-0.6%</font>) are both under modest pressure as the session nears the finish line.</li><li>No particular company-specific news accounts for the action, although the FDA is proposing a restriction on compounding three commercially available drugs. Endo International rallied on the news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385916-endo-5-percent-fda-plan-restrict-compounding-vasopressin\" target=\"_blank\">Endo up 5% on FDA plan to restrict compounding of vasopressin</a> (Aug. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385936\" data-linked=\"Specialty pharmacy operators in the red\" data-tweet=\"$REPH $REPH $DPLO - Specialty pharmacy operators in the red https://seekingalpha.com/news/3385936-specialty-pharmacy-operators-in-red?source=tweet\" data-url=\"https://seekingalpha.com/news/3385936-specialty-pharmacy-operators-in-red\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385933\" data-ts=\"1535398048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385933-game-on-again-for-tesla-production-forecasts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Game on again for Tesla production forecasts</a></h4><ul><li>Tesla's (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='red'>-1.6%</font>) Fremont factory is back in the spotlight as investors gauge the impact on production of the go-private distractions around the company in August and jump back into the game of forecasting the weekly production rate</li><li>Electrek posted its&nbsp;<a href=\"https://electrek.co/2018/08/27/tesla-on-track-production-record-this-quarter-behind-model-3-goal/\" target=\"_blank\">update</a>&nbsp;today on the production count, saying it was tipped by a \"reliable source\" that Tesla produced just over 47K vehicles in Q3 through the end of last week, including just under 30K Model 3 cars.</li><li>Per those Electrek numbers, Tesla would have to ramp up Model 3 production for the remainder of the quarter to hit the low end of its goal for 50K to 55K Model 3s produced for the full period.</li><li>Meanwhile, Bloomberg's <a href=\"https://www.bloomberg.com/news/articles/2018-08-27/tesla-flirted-with-model-3-milestone-as-musk-was-mulling-buyout\" target=\"_blank\">Model 3 tracker</a> is showing a tally of 36,710 Model 3s produced and also indicates the company briefly passed a 6K Model 3 per week pace.</li><li>Looking back at Q2, Tesla produced 53,339 vehicles during the quarter and delivered 40,768 vehicles (22,319 Model S/X vehicles and 18,449 Model 3 vehicles).</li><li>Underlying all the forecasts coming in, there's the question if Tesla will pull back on its production pace as it approaches its guidance mark in order to improve the operating cash flow tally at the end of the quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385933\" data-linked=\"Game on again for Tesla production forecasts\" data-tweet=\"$TSLA - Game on again for Tesla production forecasts https://seekingalpha.com/news/3385933-game-on-again-for-tesla-production-forecasts?source=tweet\" data-url=\"https://seekingalpha.com/news/3385933-game-on-again-for-tesla-production-forecasts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>176&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385931\" data-ts=\"1535397741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRDM\" target=\"_blank\">IRDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385931-iridiumminus-6_1-longtime-bull-backs-off-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium -6.1% as longtime bull backs off rating</a></h4><ul>   <li>Iridium Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/IRDM' title='Iridium Communications Inc'>IRDM</a>) has taken a tumble, <font color='red'>down 6.1%</font>, after longtime strong bull Sidoti backs off to Neutral on the shares based on current valuation.</li>    <li>The stock has baked in a shift to positive free cash flow generation coming in 2019, analyst Gregory Burns says; his firm has had a Buy rating up since 2013. A few catalysts will take time, he writes: It will be six to 12 months before we can assess adoption of the new Certus Broadband offering, and while the Defense Dept. is likely to renew its contract, that resolution is six to eight months out. (h/t Bloomberg)</li>    <li>Iridium has doubled over the past year (<font color='green'>up 100.5%</font>) and is <font color='green'>up 77.5%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385931\" data-linked=\"Iridium -6.1% as longtime bull backs off rating\" data-tweet=\"$IRDM - Iridium -6.1% as longtime bull backs off rating https://seekingalpha.com/news/3385931-iridiumminus-6_1-longtime-bull-backs-off-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3385931-iridiumminus-6_1-longtime-bull-backs-off-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385930\" data-ts=\"1535397030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWK\" target=\"_blank\">CWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385930-cushman-wakefield-gains-least-six-analysts-give-buy-rating-marketwatch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cushman &amp; Wakefield gains as at least six analysts give a `buy&#39; rating: MarketWatch</a></h4><ul><li>Shares of commercial real estate services recent real estate services firm Cushman &amp; Wakefield (NYSE:<a href='https://seekingalpha.com/symbol/CWK' title='Cushman & Wakefield'>CWK</a>)<font color='green'> rise 1.7%</font>&nbsp;Monday as a number of analysts<a href=\"https://www.marketwatch.com/story/cushman-wakefields-stock-boosted-as-at-least-5-analysts-rate-it-a-buy-2018-08-27\" target=\"_blank\"> issue bullish notes</a>.</li><li>The company raised $765M from its initial public offering on Aug. 1 and used the proceeds to pay down debt and to use for \"general corporate purposes. The company's main competitors are CBRE (<a href='https://seekingalpha.com/symbol/CBRE' title='CBRE Group, Inc.'>CBRE</a> <font color='green'>+0.6%</font>) and Jones Lang LaSalle (<a href='https://seekingalpha.com/symbol/JLL' title='Jones Lang Lasalle Inc.'>JLL</a> <font color='red'>-0.3%</font>).</li><li>A strong economy and real estate market provides a solid base for growth combined with a trend toward outsourcing real estate services, a Credit Suisse note says, according the MarketWatch. Credit Suisse's Douglas Harter rates CWK outperform with a $21 price target, giving it a 17% upside risk.</li><li>Goldman Sachs rates the stock a buy and expects EBITDA growth of 21% for the next two years, vs and expected 14% growth rate at broker peers.</li><li>JPMorgan initiates coverage with an overweight rating and a $12 year-end 2019 price target.</li><li>Cushman has a strong position in outsourcing, generating about 47% of its revenue from outsourcing services, analysts say. That division provides long, multiyear contracts that include fixed-pricing components. That the company performs many of those services itself--such as janitorial and engineering services--gives it more control over outcomes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3377748-cushman-and-wakefield-opens-trading-5_9-percent-pop\" target=\"_blank\">Cushman &amp; Wakefield opens trading with 5.9% pop</a> (Aug. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385930\" data-linked=\"Cushman &amp; Wakefield gains as at least six analysts give a `buy&#39; rating: MarketWatch\" data-tweet=\"$CWK $CWK $CBRE - Cushman &amp; Wakefield gains as at least six analysts give a `buy&#39; rating: MarketWatch https://seekingalpha.com/news/3385930-cushman-wakefield-gains-least-six-analysts-give-buy-rating-marketwatch?source=tweet\" data-url=\"https://seekingalpha.com/news/3385930-cushman-wakefield-gains-least-six-analysts-give-buy-rating-marketwatch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385927\" data-ts=\"1535396130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385927-technology-top-5-gainers-losers-of-2_55-pm-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (08/27/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/DBD' title='Diebold Nixdorf'>DBD</a> <font color='green'>+8%</font>.</li>      <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LRAD' title='LRAD Corp'>LRAD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/IRDM' title='Iridium Communications Inc'>IRDM</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385927\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (08/27/2018)\" data-tweet=\"$HMNY $HMNY $KONE - Technology - Top 5 Gainers / Losers as of 2.55 PM (08/27/2018) https://seekingalpha.com/news/3385927-technology-top-5-gainers-losers-of-2_55-pm-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385927-technology-top-5-gainers-losers-of-2_55-pm-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385925\" data-ts=\"1535395027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385925-stifel-sees-small-caps-rising-through-year-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel sees small caps rising through year end</a></h4><ul><li>Small-cap stocks' gains this year will continue for the rest of the year on strong financial performance and the benefits of tax reform,<a href=\"https://www.cnbc.com/2018/08/27/stifel-says-buy-small-cap-stocks-on-improving-business-environment.html?__source=twitter%7Cmain\" target=\"_blank\"> CNBC reports</a>, citing a Stifel note to investors.</li><li>Last December, the U.S. corporate tax rate was permanently cut to 21% from 35%.</li><li>\"As we move into the second half of the year, the market environment is positioned well for U.S. small cap equities to remain one of the preferred markets,\" global head of investment strategy Michael O'Keeffe said in a note to clients.</li><li>Small business owners expect increased sales and even better business conditions for the rest of year, which should boost investment spending and help fuel GDP growth, O'Keeffe wrote.</li><li>With generally less exposure to international markets than companies in the S&amp;P 500, they'll do better if the trade environment deteriorates, he said.</li><li>The Russell 200 has risen 12.8% YTD, compared with the S&amp;P 500 Index, which is up 8.3% in the same period. the Russell 200 Index is&nbsp;<font color='green'>up 0.35%</font>&nbsp;to 1,731.69 on Monday, while the S&amp;P is&nbsp;<font color='green'>up 0.7%</font>&nbsp;to 2,895.57 after President Trump announced a trade pact with Mexico.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IJS' title='iShares S&P Small-Cap 600 Value ETF'>IJS</a>, <a href='https://seekingalpha.com/symbol/VBR' title='Vanguard Small-Cap Value ETF'>VBR</a>, <a href='https://seekingalpha.com/symbol/VBK' title='Vanguard Small Cap Growth ETF'>VBK</a>, <a href='https://seekingalpha.com/symbol/RVT' title='Royce Value Trust'>RVT</a>, <a href='https://seekingalpha.com/symbol/IWN' title='iShares Russell 2000 Value ETF'>IWN</a>, <a href='https://seekingalpha.com/symbol/FFTY' title='Innovator IBD 50 Fund'>FFTY</a>, <a href='https://seekingalpha.com/symbol/IWO' title='iShares Russell 2000 Growth ETF'>IWO</a>, <a href='https://seekingalpha.com/symbol/EES' title='WisdomTree SmallCap Earnings ETF'>EES</a>, <a href='https://seekingalpha.com/symbol/IJT' title='iShares S&P Small-Cap 600 Growth ETF'>IJT</a>, <a href='https://seekingalpha.com/symbol/SLYG' title='SPDR S&P 600 Small Cap Growth ETF'>SLYG</a>, <a href='https://seekingalpha.com/symbol/SLYV' title='SPDR S&P 600 Small Cap Value ETF'>SLYV</a>, <a href='https://seekingalpha.com/symbol/RZV' title='Invesco S&P Smallcap 600 Pure Value ETF'>RZV</a>, <a href='https://seekingalpha.com/symbol/FNDA' title='Schwab Fundamental U.S. Small Company ETF'>FNDA</a>, <a href='https://seekingalpha.com/symbol/VIOG' title='Vanguard S&P Small-Cap 600 Growth ETF'>VIOG</a>, <a href='https://seekingalpha.com/symbol/VIOV' title='Vanguard S&P Small-Cap 600 Value ETF'>VIOV</a>, <a href='https://seekingalpha.com/symbol/VTWG' title='Vanguard Russell 2000 Growth ETF'>VTWG</a>, <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a>, <a href='https://seekingalpha.com/symbol/RZG' title='Invesco S&P SmallCap 600 Pure Growth ETF'>RZG</a>, <a href='https://seekingalpha.com/symbol/JKL' title='iShares Morningstar Small-Cap Value ETF'>JKL</a>, <a href='https://seekingalpha.com/symbol/VTWV' title='Vanguard Russell 2000 Value ETF'>VTWV</a>, <a href='https://seekingalpha.com/symbol/PXSV' title='Invesco Fundamental Pure Small Value Portfolio ETF'>PXSV</a>, <a href='https://seekingalpha.com/symbol/TILT' title='FlexShares Morningstar U.S. Market Factor Tilt Index ETF'>TILT</a>, <a href='https://seekingalpha.com/symbol/JKK' title='iShares Morningstar Small-Cap Growth ETF'>JKK</a>, <a href='https://seekingalpha.com/symbol/FYT' title='First Trust Small Cap Value AlphaDEX ETF'>FYT</a>, <a href='https://seekingalpha.com/symbol/VLU' title='SPDR S&P 1500 Value Title ETF'>VLU</a>, <a href='https://seekingalpha.com/symbol/FYC' title='First Trust Small Cap Growth AlphaDEX ETF'>FYC</a>, <a href='https://seekingalpha.com/symbol/PXSG-OLD' title='Invesco Fundamental Pure Small Growth Portfolio ETF'>PXSG-OLD</a>, <a href='https://seekingalpha.com/symbol/JSML' title='Janus Small Cap Growth Alpha ETF'>JSML</a>, <a href='https://seekingalpha.com/symbol/DESC' title='Deutsche X-trackers Russell 2000 Comprehensive Factor ETF'>DESC</a>, <a href='https://seekingalpha.com/symbol/USVM' title='USAA MSCI USA Small Cap Value Momentum Blend Index ETF'>USVM</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3379477-small-cap-mid-cap-indexes-hit-records-s-and-p-trails\" target=\"_blank\">Small-cap and mid-cap indexes hit records, as S&amp;P trails</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385925\" data-linked=\"Stifel sees small caps rising through year end\" data-tweet=\"$IJS $VBR $VBK - Stifel sees small caps rising through year end https://seekingalpha.com/news/3385925-stifel-sees-small-caps-rising-through-year-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3385925-stifel-sees-small-caps-rising-through-year-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385921\" data-ts=\"1535392850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAC\" target=\"_blank\">LAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385921-energy-materials-top-5-gainers-losers-of-2-00-pm-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials- Top 5 Gainers / Losers as of 2:00 PM (08/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LAC' title='Lithium Americas Corp.'>LAC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/GURE' title='GULF RESOURCES INC'>GURE</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385921\" data-linked=\"Energy/Materials- Top 5 Gainers / Losers as of 2:00 PM (08/27/2018)\" data-tweet=\"$LAC $LAC $LEU - Energy/Materials- Top 5 Gainers / Losers as of 2:00 PM (08/27/2018) https://seekingalpha.com/news/3385921-energy-materials-top-5-gainers-losers-of-2-00-pm-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385921-energy-materials-top-5-gainers-losers-of-2-00-pm-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385920\" data-ts=\"1535392514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CX\" target=\"_blank\">CX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385920-mexican-adrs-on-move-after-trade-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mexican ADRs on the move after trade deal</a></h4><ul><li>The president <a href=\"https://seekingalpha.com/news/3385886-stock-markets-record-highs-u-s-mexico-reach-trade-deal\" target=\"_blank\">earlier announced</a> agreement with Mexico on a new trade pact to replace NAFTA. Major averages on both sides of the Rio Grande are in the green. A check of Mexican ADRs:</li><li>Cemex (<a href='https://seekingalpha.com/symbol/CX' title='Cemex, S.A.B. de C.V.'>CX</a> <font color='green'>+5.2%</font>), America Movil (<a href='https://seekingalpha.com/symbol/AMX' title='America Movil SA de CV'>AMX</a> <font color='green'>+1.4%</font>), Banco Santander Mexico (<a href='https://seekingalpha.com/symbol/BSMX' title='Grupo Financiero Santander S.A.B. de C.V.'>BSMX</a> <font color='green'>+3.4%</font>), Grupo Televisa (<a href='https://seekingalpha.com/symbol/TV' title='Grupo Televisa, S.A.'>TV</a> <font color='green'>+2.2%</font>), Coca-Cola Femsa (<a href='https://seekingalpha.com/symbol/KOF' title='Coca-Cola FEMSA, S.A.B. De C.V.'>KOF</a> <font color='green'>+2.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385920\" data-linked=\"Mexican ADRs on the move after trade deal\" data-tweet=\"$CX $CX $AMX - Mexican ADRs on the move after trade deal https://seekingalpha.com/news/3385920-mexican-adrs-on-move-after-trade-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3385920-mexican-adrs-on-move-after-trade-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385917\" data-ts=\"1535390898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385917-amd-races-to-new-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD races to new all-time high</a></h4><ul><li>Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) is now&nbsp;<font color='green'>up 11%</font>&nbsp;as investors continue to rush in on <a href=\"https://seekingalpha.com/pr/17253517-new-amd-radeon-pro-v340-graphics-card-delivers-accelerated-performance-high-user-density\" target=\"_blank\">news</a> of the company's new graphics card.</li><li>The company says in its release that the new Radeon Pro V340 graphics card employs advanced security features and helps to cost effectively deliver and accelerate modern visualization workloads from the datacenter.</li><li>Separately, AMD also <a href=\"https://www.engadget.com/2018/08/26/amd-prevails-in-patent-fight-with-vizio-over-tv-graphics/\" target=\"_blank\">won</a> a patent fight with Vizio over TV graphics.</li><li>Shares of AMD carved out a new all-time high of $26.80 earlier.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385917\" data-linked=\"AMD races to new all-time high\" data-tweet=\"$AMD - AMD races to new all-time high https://seekingalpha.com/news/3385917-amd-races-to-new-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3385917-amd-races-to-new-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>218&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385916\" data-ts=\"1535390790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385916-endo-up-5-on-fda-plan-to-restrict-compounding-of-vasopressin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo up 5% on FDA plan to restrict compounding of vasopressin</a></h4><ul><li>Endo International (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='green'>+5.1%</font>) is up on average volume on the heels of the FDA's&nbsp;<a href=\"https://in.reuters.com/article/us-usa-fda-compounding/fda-proposes-restricting-compounding-of-three-drug-substances-idINKCN1LC1U7\" target=\"_blank\">proposed restriction </a>on bulk compounding of three approved drugs, including vasopressin.</li><li>The company sued the agency seeking to remove vasopressin from its authorized bulk compounding list, the inclusion of which benefited Athenex (<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color='red'>-0.5%</font>) which recently launched vasopressin in ready-to-use IV bags in the U.S.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3382084-endo-modest-pressure-athenex-vasopressin-launch-shares-3-percent\" target=\"_blank\">Endo under modest pressure on Athenex vasopressin launch, shares down 3%</a> (Aug. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385916\" data-linked=\"Endo up 5% on FDA plan to restrict compounding of vasopressin\" data-tweet=\"$ENDP $ENDP $ATNX - Endo up 5% on FDA plan to restrict compounding of vasopressin https://seekingalpha.com/news/3385916-endo-up-5-on-fda-plan-to-restrict-compounding-of-vasopressin?source=tweet\" data-url=\"https://seekingalpha.com/news/3385916-endo-up-5-on-fda-plan-to-restrict-compounding-of-vasopressin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385910\" data-ts=\"1535389432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385910-keyw-gets-gsa-purchase-agreement-valued-135m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyW gets GSA purchase agreement valued at $135M</a></h4><ul><li>KeyW Holding&nbsp;<font color='green'>rises 2.7%</font>&nbsp;after announcing it<a href=\"https://seekingalpha.com/pr/17254013-keyw-wins-award-gsa-s-135-million-remote-sensing-command-control-communications-computer-idiq\" target=\"_blank\">&nbsp;will provide </a>services across the remote sensing, command control communications, and computer mission areas under a blanket purchase agreement to support the Department of Defense and Defense agencies.</li><li>The multiple award BPA has an estimated value of $135M over five years.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384525-keyw-plus-3_5-percent-100m-contract-classified-customer\" target=\"_blank\">KeyW +3.5% on over $100M contract with classified customer</a> (Aug. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385910\" data-linked=\"KeyW gets GSA purchase agreement valued at $135M\" data-tweet=\"KeyW gets GSA purchase agreement valued at $135M https://seekingalpha.com/news/3385910-keyw-gets-gsa-purchase-agreement-valued-135m?source=tweet\" data-url=\"https://seekingalpha.com/news/3385910-keyw-gets-gsa-purchase-agreement-valued-135m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385908\" data-ts=\"1535389319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YRD\" target=\"_blank\">YRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385908-financials-top-5-gainers-losers-of-1-00-pm-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (08/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CIA' title='Citizens, Inc.'>CIA</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/BBDO' title='Banco Bradesco S.A.'>BBDO</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CPSS' title='Consumer Portfolio Services, Inc.'>CPSS</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd. ADS'>LX</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385908\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (08/27/2018)\" data-tweet=\"$YRD $YRD $XRF - Financials - Top 5 Gainers / Losers as of 1:00 PM (08/27/2018) https://seekingalpha.com/news/3385908-financials-top-5-gainers-losers-of-1-00-pm-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385908-financials-top-5-gainers-losers-of-1-00-pm-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385904\" data-ts=\"1535388492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIS\" target=\"_blank\">TIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385904-midday-gainers-losers-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (08/27/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/JMEI' title='Jumei International Holding Limited'>JMEI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/CTXR' title='Citius Pharmaceuticals Inc.'>CTXR</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/LAC' title='Lithium Americas Corp.'>LAC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/LEVB' title='Level Brands, Inc.'>LEVB</a> <font color='green'>+13%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/EIDX' title='Eidos Therapeutics'>EIDX</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GURE' title='GULF RESOURCES INC'>GURE</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BBW' title='Build-A-Bear Workshop, Inc.'>BBW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CDZI' title='Cadiz, Inc.'>CDZI</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3385904\" data-linked=\"Midday Gainers / Losers (08/27/2018)\" data-tweet=\"$TIS $TIS $HMNY - Midday Gainers / Losers (08/27/2018) https://seekingalpha.com/news/3385904-midday-gainers-losers-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385904-midday-gainers-losers-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385900\" data-ts=\"1535387661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385900-adamis-pharma-expects-fda-nod-for-low-dose-symjepi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis Pharma expects FDA nod for low-dose Symjepi</a></h4><ul><li>In an <a href=\"https://seekingalpha.com/pr/17254199-adamis-pharmaceuticals-provides-business-update\" target=\"_blank\">update </a>for investors, Adamis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='red'>-2.7%</font>) President &amp; CEO Dr. Dennis Carlo says the company expects the FDA to give a thumbs up to a lower dose formulation of emergency allergy med Symjepi (epinephrine) Injection 0.15 mg. The agency's action is September 27.</li><li>It has selected Novartis unit Sandoz to launch the product in the U.S. (the FDA approved the 0.30 mg version in November 2017). The specific timing has yet to be announced, however.</li><li>Symjepi is not an auto-injector like EpiPen, but rather a prefilled syringe.</li><li>Future key milestones include the filing of U.S. marketing applications for naloxone injection and sublingual tadalafil (Cialis) and the launch of Phase 3 studies of beclomethasone.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385900\" data-linked=\"Adamis Pharma expects FDA nod for low-dose Symjepi\" data-tweet=\"$ADMP - Adamis Pharma expects FDA nod for low-dose Symjepi https://seekingalpha.com/news/3385900-adamis-pharma-expects-fda-nod-for-low-dose-symjepi?source=tweet\" data-url=\"https://seekingalpha.com/news/3385900-adamis-pharma-expects-fda-nod-for-low-dose-symjepi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385899\" data-ts=\"1535387384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDFS\" target=\"_blank\">PDFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385899-michael-b-gustafson-joins-pdf-solutions-board-of-directors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Michael B. Gustafson joins PDF Solutions board of directors</a></h4><ul>     <li>PDF Solutions (<a href='https://seekingalpha.com/symbol/PDFS' title='PDF Solutions, Inc.'>PDFS</a> <font color='green'>+2.5%</font>) says that Michael B. Gustafson has joined the Company&rsquo;s Board of Directors effective Aug. 27, 2018.</li>     <li>Mr. Gustafson is currently Executive Chairman and Independent Board Director at Druva Inc. a cloud data protection and management company, and a member of the Board of Directors of Everspin Technologies.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3379070-pdf-solutions-names-christine-russell-cfo\" target=\"_blank\">PDF Solutions names Christine Russell as CFO</a> (Aug. 7)</li><li><a href=\"https://seekingalpha.com/pr/17253778-michael-b-gustafson-joins-pdf-solutions-board-directors\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3385899\" data-linked=\"Michael B. Gustafson joins PDF Solutions board of directors\" data-tweet=\"$PDFS - Michael B. Gustafson joins PDF Solutions board of directors https://seekingalpha.com/news/3385899-michael-b-gustafson-joins-pdf-solutions-board-of-directors?source=tweet\" data-url=\"https://seekingalpha.com/news/3385899-michael-b-gustafson-joins-pdf-solutions-board-of-directors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385896\" data-ts=\"1535386454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385896-seven-stars-cloud-announces-business-name-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Cloud announces business name change</a></h4><ul>     <li>Seven Stars Cloud Group (<a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='red'>-6.1%</font>) <a href=\"https://seekingalpha.com/pr/17254191-seven-stars-cloud-announces-business-name-change-ideanomics\" target=\"_blank\">announced</a> the adoption of Ideanomics as its new business name subject to shareholder approval.</li>     <li>Shares of Ideanomics, will continue to trade on Nasdaq using the Company's existing ticker symbol, \"SSC\".</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385896\" data-linked=\"Seven Stars Cloud announces business name change\" data-tweet=\"$SSC-OLD - Seven Stars Cloud announces business name change https://seekingalpha.com/news/3385896-seven-stars-cloud-announces-business-name-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3385896-seven-stars-cloud-announces-business-name-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385895\" data-ts=\"1535386190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAN\" target=\"_blank\">MAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385895-manpower-jumps-after-argus-backs-bullish-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manpower jumps after Argus backs bullish view</a></h4><ul> <li>Shares of Manpower Group (<a href='https://seekingalpha.com/symbol/MAN' title='ManpowerGroup Inc.'>MAN</a> <font color='green'>+5.6%</font>) are on the rise after Argus maintains a Buy rating on the workforce solutions stock in a new update to investors.</li> <li>Snippets from analyst Jasper Hellweg's note: \"The company has posted solid EPS growth for several years, and appears poised for continued strong gains, particularly in Europe, amid improving global economic and labor market conditions... Management has also expressed confidence about a return to revenue growth in the U.S. We expect margins to improve as the company completes its restructuring... We believe that MAN shares are favorably valued at 10.2-times our 2018 EPS estimate, toward the low end of the five-year historical range of 9.4-20.6 and below the peer average of 18.9.\"</li> <li>Argus assigns a price target of $107 to Manpower vs. the 52-week trading range of $81.85 to $136.93.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3385895\" data-linked=\"Manpower jumps after Argus backs bullish view\" data-tweet=\"$MAN - Manpower jumps after Argus backs bullish view https://seekingalpha.com/news/3385895-manpower-jumps-after-argus-backs-bullish-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3385895-manpower-jumps-after-argus-backs-bullish-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385890\" data-ts=\"1535385641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIS\" target=\"_blank\">TIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385890-consumer-top-5-gainers-losers-of-12-00-pm-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top 5 Gainers / Losers as of 12:00 PM (08/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/AMWD' title='American Woodmark Corporation'>AMWD</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385890\" data-linked=\"Consumer - Top 5 Gainers / Losers as of 12:00 PM (08/27/2018)\" data-tweet=\"$TIS $TIS $YGYI - Consumer - Top 5 Gainers / Losers as of 12:00 PM (08/27/2018) https://seekingalpha.com/news/3385890-consumer-top-5-gainers-losers-of-12-00-pm-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385890-consumer-top-5-gainers-losers-of-12-00-pm-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385876\" data-ts=\"1535384389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385876-money-flow-stays-positive-in-biotechs-xbi-up-6-since-last-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Money flow stays positive in biotechs, XBI up 6% since last week</a></h4><ul><li>Biotechs continue their modest rally. The SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='green'>+1.9%</font>) is up albeit on below average. It has jumped&nbsp;<font color='green'>6%</font>&nbsp;since last week.</li><li>Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='green'>+8.9%</font>) and Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+20.7%</font>) are <a href=\"https://seekingalpha.com/news/3385829-alnylam-ionis-lower-perceived-threat-pfizers-tafamidis-attr\" target=\"_blank\">leading the way</a> as investors perceive improved prospects for inotersen and patisiran, respectively, after Pfizer released late-stage data on tafamidis.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+2.7%</font>)(<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='green'>+1.3%</font>)(<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a> <font color='green'>+4%</font>)(<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='green'>+3.6%</font>)(<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+2.7%</font>)(<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+4.1%</font>)(<a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a> <font color='green'>+2.5%</font>)(<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='green'>+2.9%</font>)(<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+2.6%</font>)(<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+1.2%</font>)(<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+3.5%</font>)(<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color='green'>+4.6%</font>)(<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color='green'>+1.9%</font>)(<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='green'>+5.1%</font>)(<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='green'>+3%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+1.6%</font>)(<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+4%</font>)(<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a> <font color='green'>+2.7%</font>)(<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color='green'>+3.3%</font>)(<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+0.1%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+2.2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385876\" data-linked=\"Money flow stays positive in biotechs, XBI up 6% since last week\" data-tweet=\"$IONS $XBI $IONS - Money flow stays positive in biotechs, XBI up 6% since last week https://seekingalpha.com/news/3385876-money-flow-stays-positive-in-biotechs-xbi-up-6-since-last-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3385876-money-flow-stays-positive-in-biotechs-xbi-up-6-since-last-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385869\" data-ts=\"1535382823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTX\" target=\"_blank\">PTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385869-pernix-therapeutics-continues-slide-down-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pernix Therapeutics continues slide, down 12%</a></h4><ul><li>Thinly traded nano cap Pernix Therapeutics (<a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-11.8%</font>) is down on more than double normal, albeit on turnover of only 177K shars. The stock has lost over half its value in a month.</li><li>Share have sold off amidst the flurry of activity aimed at reining in the opioid crisis, creating headwinds for top seller Zohydro ER (hydrocodone bitartrate). Q2 sales were $8.3M (+28%) due mainly to a price increase.</li><li>The company is part of an investor group that recently acquired the assets of Orexigen, maker of weight loss med Contrave (naltrexone HCl), via a special purpose entity called Nalpropion Pharmaceuticals. 5% of Contrave sales will go to Pernix as a management fee.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3347626-orexigen-agrees-sell-nalpropion-pharma-75m-shares-34-percent\" target=\"_blank\">Orexigen agrees to sell itself to Nalpropion Pharma for $75M; shares down 34%</a> (April 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385869\" data-linked=\"Pernix Therapeutics continues slide, down 12%\" data-tweet=\"$PTX $PTX-OLD - Pernix Therapeutics continues slide, down 12% https://seekingalpha.com/news/3385869-pernix-therapeutics-continues-slide-down-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3385869-pernix-therapeutics-continues-slide-down-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385870\" data-ts=\"1535382696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385870-new-telesat-high-throughput-satellite-enters-commercial-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Telesat high-throughput satellite enters commercial service</a></h4><ul>   <li>Telesat says its new Telstar 19 VANTAGE satellite is <a href=\"https://seekingalpha.com/pr/17253635-telesat-s-new-telstar-19-vantage-satellite-now-operational\" target=\"_blank\">fully operational</a> and has entered commercial service.</li>    <li>The high-throughput satellite, built by Maxar's (<a href=\"http://seekingalpha.com/symbol/MAXR\" target=\"_blank\">MAXR</a> <font color='red'>-1.9%</font>) SSL, will serve consumer, enterprise and mobility markets across the Americas and Atlantic.</li>    <li>It combines regional beams and high-throughput spot beams in the Ku band, with additional HTS spot beams in the Ka band.</li>    <li>Hughes Network Systems (<a href=\"http://seekingalpha.com/symbol/SATS\" target=\"_blank\">SATS</a> <font color='green'>+0.5%</font>) has signed a 15-year agreement for the bird's Ka-band capacity, which it will use for expanding broadband satellite for consumers and businesses in South America. Telesat also has long-term deals for the entire Ka-band capacity over Northern Canada.</li>    <li>Telesat's principal shareholders are Loral Space &amp; Communications (<a href=\"http://seekingalpha.com/symbol/LORL\" target=\"_blank\">LORL</a> <font color='green'>+1.5%</font>) and Canada's Public Sector Pension Investment Board.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385870\" data-linked=\"New Telesat high-throughput satellite enters commercial service\" data-tweet=\"$MAXR $MAXR $SATS - New Telesat high-throughput satellite enters commercial service https://seekingalpha.com/news/3385870-new-telesat-high-throughput-satellite-enters-commercial-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3385870-new-telesat-high-throughput-satellite-enters-commercial-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385868\" data-ts=\"1535382202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APO\" target=\"_blank\">APO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385868-report-aspen-apollo-near-deal-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Aspen/Apollo near deal; shares up more than 4%</a></h4><ul><li><a href=\"https://www.insuranceinsider.com/articles/121327/apollo-poised-to-clinch-26bn-aspen-takeover\" target=\"_blank\">According to Insurance Insider</a>, Apollo Global (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>) is near a deal for Aspen Insurance (NYSE:<a href='https://seekingalpha.com/symbol/AHL' title='Aspen Insurance Holdings Limited'>AHL</a>) at $42-$43 per share. That's a deal value of about $2.6B <a href=\"https://seekingalpha.com/news/3384084-aspen-rises-2_9-percent-nears-2_5b-deal-apollo-insurance-insider\" target=\"_blank\">vs. the $2.5B floated </a>last week.</li><li>AHL is<font color='green'> higher by 4.2%</font>&nbsp;to $40.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385868\" data-linked=\"Report: Aspen/Apollo near deal; shares up more than 4%\" data-tweet=\"$APO $APO $AHL - Report: Aspen/Apollo near deal; shares up more than 4% https://seekingalpha.com/news/3385868-report-aspen-apollo-near-deal-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3385868-report-aspen-apollo-near-deal-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385865\" data-ts=\"1535382057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIVO\" target=\"_blank\">TIVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385865-tivoplus-4_6-b-riley-sees-69-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TiVo +4.6% as B. Riley sees 69% upside</a></h4><ul>   <li>TiVo (NASDAQ:<a href='https://seekingalpha.com/symbol/TIVO' title='TiVo Inc.'>TIVO</a>) is <font color='green'>up 4.6%</font> after B. Riley FBR reiterates its Buy rating and boosts its target price to $23, from $19.</li>    <li>That implies 69% upside from today's already higher price.</li>    <li>B. Riley added TiVo to its Alpha Generator, pointing to compelling opportunity from TiVo's ongoing strategic review, which could yet end up with a few favorable outcomes; the company could sell its product segment, use net operating losses to shield gains and take its IP licensing segment private, notes analyst Eric Wold. (h/t Bloomberg)</li>    <li>Valuation has been held down by investor focus on the company's litigation with Comcast, he notes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3383921-tivo-sinks-report-amazon-dvr-plans-updated\" target=\"_blank\">TiVo sinks on report of Amazon DVR plans (updated)</a> (Aug. 17 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3380621-tivo-plus-4_9-percent-quarter-report-updates-strategic-review\" target=\"_blank\">TiVo +4.9% as quarter report updates strategic review</a> (Aug. 08 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3379821-tivo-loses-another-patent-battle-comcast\" target=\"_blank\">TiVo loses another patent battle to Comcast</a> (Aug. 07 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385865\" data-linked=\"TiVo +4.6% as B. Riley sees 69% upside\" data-tweet=\"$TIVO - TiVo +4.6% as B. Riley sees 69% upside https://seekingalpha.com/news/3385865-tivoplus-4_6-b-riley-sees-69-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3385865-tivoplus-4_6-b-riley-sees-69-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385864\" data-ts=\"1535382028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385864-healthcare-top-5-gainers-losers-of-11-00-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CTXR' title='Citius Pharmaceuticals Inc.'>CTXR</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EIDX' title='Eidos Therapeutics'>EIDX</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/VCEL' title='Vericel Corporation'>VCEL</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385864\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/27/2018)\" data-tweet=\"$CRON $CRON $TLRY - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (08/27/2018) https://seekingalpha.com/news/3385864-healthcare-top-5-gainers-losers-of-11-00-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385864-healthcare-top-5-gainers-losers-of-11-00-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385862\" data-ts=\"1535381945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FANH\" target=\"_blank\">FANH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385862-fanhua-down-12_8-seeking-alpha-contributor-talks-fraud\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fanhua down 12.8% as Seeking Alpha contributor talks fraud</a></h4><ul><li>New Seeking Alpha contributor <a href=\"https://seekingalpha.com/article/4202238-fanhua-inc-questionable-company-history-alleged-fraud-potential-79minus-100-percent-downside\" target=\"_blank\">Seligman Investments calls</a> Fanhua (<a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-12.8%</font>) a \"questionable company,\" and checks into a history of alleged fraud. Potential downside:&nbsp;<font color='red'>79-100%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385862\" data-linked=\"Fanhua down 12.8% as Seeking Alpha contributor talks fraud\" data-tweet=\"$FANH - Fanhua down 12.8% as Seeking Alpha contributor talks fraud https://seekingalpha.com/news/3385862-fanhua-down-12_8-seeking-alpha-contributor-talks-fraud?source=tweet\" data-url=\"https://seekingalpha.com/news/3385862-fanhua-down-12_8-seeking-alpha-contributor-talks-fraud\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385856\" data-ts=\"1535380688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIDX\" target=\"_blank\">EIDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385856-eidos-therapeutics-down-32-on-positive-data-for-pfizers-tafamidis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eidos Therapeutics down 32% on positive data for Pfizer&#39;s tafamidis</a></h4><ul><li>Thinly traded Eidos Therapeutics (<a href='https://seekingalpha.com/symbol/EIDX' title='Eidos Therapeutics'>EIDX</a> <font color='red'>-31.7%</font>) slumps almost a 4x surge in volume on the heels of Pfizer's data release on tafamidis in patients with transthyretin amyloid cardiomyopathy.</li><li>Eidos' candidate for the same condition is Phase 2-stage&nbsp;<a href=\"https://eidostx.com/physicians/\" target=\"_blank\">AG10</a> which has a similar mechanism of action. Investors clearly perceive diminished prospects for AG10 in light of Pfizer's lead and likelihood of earlier approval.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385759-pfizers-tafamidis-shows-positive-effect-late-stage-attr-cm-study-shares-1-percent-premarket\" target=\"_blank\">Pfizer's tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket</a> (Aug. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385856\" data-linked=\"Eidos Therapeutics down 32% on positive data for Pfizer&#39;s tafamidis\" data-tweet=\"$EIDX - Eidos Therapeutics down 32% on positive data for Pfizer&#39;s tafamidis https://seekingalpha.com/news/3385856-eidos-therapeutics-down-32-on-positive-data-for-pfizers-tafamidis?source=tweet\" data-url=\"https://seekingalpha.com/news/3385856-eidos-therapeutics-down-32-on-positive-data-for-pfizers-tafamidis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385851\" data-ts=\"1535380011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIHO\" target=\"_blank\">HIHO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385851-on-highway-holdings-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Highway Holdings Q1 results</a></h4><ul><li>Highway Holdings (<a href='https://seekingalpha.com/symbol/HIHO' title='Highway Holdings Limited'>HIHO</a> <font color='red'>-2%</font>) reported Q1 revenue of $4.05M a decrease of 23.7% Y/Y, reflecting reduction in orders from two of the larger OEM customers.</li><li>Q1 Gross margin&nbsp;<font color='red'>declined by 26 bps</font>&nbsp;to 25.7% and operating margin&nbsp;<font color='red'>declined by 356 bps</font>&nbsp;to 1.04%.</li><li>SG&amp;A expenses were $1M a decrease of 11.9% Y/Y and margin was at 24.7%&nbsp;<font color='red'>up by 330 bps</font>, due to steep decrease in net sales.</li><li>Inventories were at $2.78M a decline of -5.1% compared to last quarter.</li><li>Company has cash and restricted cash of $10.4M as of June 30, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385780-highway-holdings-reports-q1-results\" target=\"_blank\">Highway Holdings reports Q1 results</a> (Aug. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385851\" data-linked=\"More on Highway Holdings Q1 results\" data-tweet=\"$HIHO - More on Highway Holdings Q1 results https://seekingalpha.com/news/3385851-on-highway-holdings-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3385851-on-highway-holdings-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385841\" data-ts=\"1535379727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385841-sell-siders-bullish-on-pfizer-tafamidis-after-release-of-positive-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders bullish on Pfizer tafamidis after release of positive data</a></h4><ul><li>Sell-side analysts weigh in on Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-1.9%</font>) Vyndaqel (tafamidis) after the company released late-stage data in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy.</li><li>Barclays' Geoff Meacham (EQUAL WEIGHT/$40): Data should support U.S. approval and expanced label in Europe next year. Peak sales could reach $1B despite lack of evidence of a clear dose response.</li><li>Cantor's Louise Chen (OVERWEIGHT/$45): Results are \"good news\" and should propel shares higher.</li><li>JPMorgan's Anupam Rama (BUY/$42): Sees Pfizer's data as a \"clearing event\" for competitors Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+15.1%</font>) (OVERWEIGHT/$126) and Eidos Therapeutics (<a href='https://seekingalpha.com/symbol/EIDX' title='Eidos Therapeutics'>EIDX</a> <font color='red'>-32.5%</font>) with AG10 citing \"plenty of room for differentiation\" from tafamidis (investors appear to disagree his assessment of Eidos).</li><li>Stifel's Paul Matteis: Data a \"net neutral for ALNY and AKCA (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+2.1%</font>) considering marginal 18-month results for tafamidis and higher hazard ratios compared to ALNY's ONPATTRO. [ALNY: BUY/$123; IONS: HOLD/$47; AKCA: HOLD/$33]</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385759-pfizers-tafamidis-shows-positive-effect-late-stage-attr-cm-study-shares-1-percent-premarket\" target=\"_blank\">Pfizer's tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket</a> (Aug. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385841\" data-linked=\"Sell-siders bullish on Pfizer tafamidis after release of positive data\" data-tweet=\"$PFE $PFE $ALNY - Sell-siders bullish on Pfizer tafamidis after release of positive data https://seekingalpha.com/news/3385841-sell-siders-bullish-on-pfizer-tafamidis-after-release-of-positive-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3385841-sell-siders-bullish-on-pfizer-tafamidis-after-release-of-positive-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385847\" data-ts=\"1535378946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLNW\" target=\"_blank\">LLNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385847-limelight-networksplus-9_8-craig-hallum-sees-heavy-ott-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Limelight Networks +9.8% as Craig-Hallum sees heavy OTT upside</a></h4><ul>   <li>Limelight Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a>) is <font color='green'>up 9.8%</font> after Craig-Hallum points to a potential doubling in its initiation note.</li>    <li>In starting the company at Buy, the firm has a price target of $6 (implying 25% upside) but says the stock could move 50-100% amid surging demand for over-the-top video: The stock is \"disconnected from fundamentals,\" analyst Jeff Van Rhee says. Nearly half its revenue comes from video delivery where it's set to take traffic coming from Hulu, DirecTV Now and others. (h/t Bloomberg)</li>    <li>Shares are slightly below flat for 2018, in part due to nonfundamentals like Goldman Sachs selling its 30% stake, Van Rhee says. <a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> is <font color='green'>up 22%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385847\" data-linked=\"Limelight Networks +9.8% as Craig-Hallum sees heavy OTT upside\" data-tweet=\"$LLNW - Limelight Networks +9.8% as Craig-Hallum sees heavy OTT upside https://seekingalpha.com/news/3385847-limelight-networksplus-9_8-craig-hallum-sees-heavy-ott-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3385847-limelight-networksplus-9_8-craig-hallum-sees-heavy-ott-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385838\" data-ts=\"1535378548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNNA\" target=\"_blank\">SNNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385838-sienna-bio-up-3-on-advancement-of-snaminus-125\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sienna Bio up 3% on advancement of SNA-125</a></h4><ul> <li>Sienna Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/SNNA' title='Sienna Biopharmaceuticals'>SNNA</a> <font color='green'>+2.6%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/17253993-sienna-biopharmaceuticals-announces-results-first-human-study-snaminus-125-psoriasis\" target=\"_blank\">announces</a> results from a first-in-human study of JAK3/TrkA inhibitor&nbsp;SNA-125 for the topical treatment of mild-to-moderate psoriasis.</li>      <li>The Phase 1/2, double-blind study in 15 subjects was designed to measure an effect on inflammatory skin infiltrate thickness, local tolerability, and histology and biomarkers with two doses of SNA-125 prototype gel applied once daily for 10 days.</li>  <li>SNA-125 was well-tolerated with no safety signals observed. Neither dose of SNA-125 (0.2 or 2%) reduced the inflammatory skin infiltrate thickness from baseline, but a modest reduction in epidermal thickness from baseline was observed in the 0.2% cohort.</li>    <li>Phase 2 development should start in H2 2019.</li><li>Preliminary data from a Phase 1/2 study in atopic dermatitis are expected next quarter.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3385838\" data-linked=\"Sienna Bio up 3% on advancement of SNA-125\" data-tweet=\"$SNNA - Sienna Bio up 3% on advancement of SNA-125 https://seekingalpha.com/news/3385838-sienna-bio-up-3-on-advancement-of-snaminus-125?source=tweet\" data-url=\"https://seekingalpha.com/news/3385838-sienna-bio-up-3-on-advancement-of-snaminus-125\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385839\" data-ts=\"1535378170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385839-facing-new-rules-techs-press-for-federal-privacy-law\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facing new rules, techs press for federal privacy law</a></h4><ul>   <li>Amid a rough year on the user-privacy front, major tech platforms are \"aggressively\" lobbying the Trump administration to <a href=\"https://www.nytimes.com/2018/08/26/technology/tech-industry-federal-privacy-law.html\" target=\"_blank\">create a federal privacy law</a>, one that would overrule a tougher California state law, <i>The New York Times</i> reports.</li>    <li>Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+1.6%</font>), Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='green'>+0.8%</font>), IBM (<a href=\"http://seekingalpha.com/symbol/IBM\" target=\"_blank\">IBM</a> <font color='green'>+0.8%</font>), Microsoft (<a href=\"http://seekingalpha.com/symbol/MSFT\" target=\"_blank\">MSFT</a> <font color='green'>+0.2%</font>) and others are part of the effort, paced by groups like the Information Technology Industry Council.</li>    <li>California's June law set a guidepost for the rest of the country on users' rights to know about what data is being collected and shared, but it hits the center of many Internet companies' ad-based revenue streams, dependent on such volumes of personal data.</li>    <li>Top lobbyists for tech companies agreed with Facebook's Joel Kaplan that the California law could be more problematic than Europe's General Data Protection Regulation, which spurred industrywide changes in privacy disclosures.</li>    <li>Internet companies seem to have come around to the idea that some regulation on privacy is inevitable and want to have a hand in writing the friendliest possible rules.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385839\" data-linked=\"Facing new rules, techs press for federal privacy law\" data-tweet=\"$GOOG $GOOG $GOOGL - Facing new rules, techs press for federal privacy law https://seekingalpha.com/news/3385839-facing-new-rules-techs-press-for-federal-privacy-law?source=tweet\" data-url=\"https://seekingalpha.com/news/3385839-facing-new-rules-techs-press-for-federal-privacy-law\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385829\" data-ts=\"1535377455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385829-alnylam-and-ionis-up-on-lower-perceived-threat-from-pfizers-tafamidis-in-attr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alnylam and Ionis up on lower perceived threat from Pfizer&#39;s tafamidis in ATTR</a></h4><ul><li>Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+4.6%</font>) is up in early trade on the heels of Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-0.9%</font>) announced late-stage data on tafamidis in transthyretin amyloid cardiomyopathy.</li><li>Evercore ISI's Josh Schimmer says Pfizer's data were \"strong\" but 20 mg was not differentiated from 80 mg and there was more limited efficacy in the ATTRm (hereditary) population than patisiran.</li><li>Ionic Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='green'>+2.9%</font>) is up as well on the diminished threat to inotersen. Akcea Therapeutics (<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+2.1%</font>) is up as well.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385759-pfizers-tafamidis-shows-positive-effect-late-stage-attr-cm-study-shares-1-percent-premarket\" target=\"_blank\">Pfizer's tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket</a> (Aug. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3342678-alnylam-ionis-red-positive-late-stage-data-pfizers-amyloidosis-drug-tafamidis\" target=\"_blank\">Alnylam and Ionis in the red on positive late-stage data on Pfizer's amyloidosis drug tafamidis</a> (March 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385829\" data-linked=\"Alnylam and Ionis up on lower perceived threat from Pfizer&#39;s tafamidis in ATTR\" data-tweet=\"$ALNY $ALNY $PFE - Alnylam and Ionis up on lower perceived threat from Pfizer&#39;s tafamidis in ATTR https://seekingalpha.com/news/3385829-alnylam-and-ionis-up-on-lower-perceived-threat-from-pfizers-tafamidis-in-attr?source=tweet\" data-url=\"https://seekingalpha.com/news/3385829-alnylam-and-ionis-up-on-lower-perceived-threat-from-pfizers-tafamidis-in-attr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385831\" data-ts=\"1535376883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DG\" target=\"_blank\">DG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385831-oppenheimer-confident-on-dollar-store-chains-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer confident on dollar store chains ahead of earnings</a></h4><ul> <li>Oppenheimer lifts price targets on Dollar General (<a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a> <font color='green'>+0.2%</font>) and Dollar Tree (<a href='https://seekingalpha.com/symbol/DLTR' title='Dollar Tree, Inc.'>DLTR</a> <font color='green'>+0.7%</font>) ahead of earnings reports due out later this week from both the retailers.</li> <li>Dollar store breakdown: \"We still remain constructive on the dollar store space even after the recent rally. Consistent with our views the past several months, DG remains our top pick and we consider DLTR as the higher beta play in the space given greater uncertainty with the FDO turn.\"</li> <li>The price target on Dollar General is raised to $120 from $108, while the PT on Dollar Tree goes to $108 from $92.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3385831\" data-linked=\"Oppenheimer confident on dollar store chains ahead of earnings\" data-tweet=\"$DG $DG $DLTR - Oppenheimer confident on dollar store chains ahead of earnings https://seekingalpha.com/news/3385831-oppenheimer-confident-on-dollar-store-chains-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3385831-oppenheimer-confident-on-dollar-store-chains-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385818\" data-ts=\"1535376624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZBH\" target=\"_blank\">ZBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385818-zimmer-biomet-site-receives-fda-warning-letter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zimmer Biomet site receives FDA Warning Letter</a></h4><ul><li>Zimmer Biomet Holdings' (NYSE:<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a>) Warsaw, Indiana site has <a href=\"https://www.sec.gov/Archives/edgar/data/1136869/000119312518258149/d605327d8k.htm\" target=\"_blank\">received</a> a Warning Letter from the FDA related to cGMP deficiencies.</li><li>The Warning Letter, specific to the North Campus facility, resulted from a reinspection in April and prohibits the issuance of Certificates to Foreign Governments (FDA certification that the products made there are in compliance with FDA standards) until the deficiencies are corrected.</li><li>The company expects to resolve all issues cited in the letter and does not expect it to materially impact financial results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385818\" data-linked=\"Zimmer Biomet site receives FDA Warning Letter\" data-tweet=\"$ZBH - Zimmer Biomet site receives FDA Warning Letter https://seekingalpha.com/news/3385818-zimmer-biomet-site-receives-fda-warning-letter?source=tweet\" data-url=\"https://seekingalpha.com/news/3385818-zimmer-biomet-site-receives-fda-warning-letter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385824\" data-ts=\"1535376313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGI\" target=\"_blank\">EIGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385824-endurance-internationalplus-6_3-on-strategic-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endurance International +6.3% on strategic talks</a></h4><ul>   <li>Endurance International (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGI' title='Endurance International Group Holdings, Inc.'>EIGI</a>) is <font color='green'>up 6.3%</font> premarket after Bloomberg's weekend report noted it's held talks with advisers about strategic options including a sale.</li>    <li>The company's biggest shareholders are the ones that took it public five years ago: Warburg Pincus and Goldman Sachs.</li>    <li>The move follows the <a href=\"https://seekingalpha.com/news/3365496-web-com-agrees-acquired-2b-cash-deal-shares-plus-7_8-percent\" target=\"_blank\">sale of Web.com</a> in June.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385824\" data-linked=\"Endurance International +6.3% on strategic talks\" data-tweet=\"$EIGI - Endurance International +6.3% on strategic talks https://seekingalpha.com/news/3385824-endurance-internationalplus-6_3-on-strategic-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3385824-endurance-internationalplus-6_3-on-strategic-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385822\" data-ts=\"1535375927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YY\" target=\"_blank\">YY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385822-yyplus-2-blue-lotus-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YY +2% as Blue Lotus boosts to Buy</a></h4><ul>   <li>ADRs of China's <a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a> are <font color='green'>up 2%</font> premarket after an upgrade to Buy at Blue Lotus Capital Advisors.</li>    <li>The firm boosted its recommendation from Hold and raised its price target to $107 from $95, implying 39% upside.</li>    <li><a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a> is <font color='red'>down 31.9%</font> YTD but is on the upswing over the past week (<font color='green'>up 4.6%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385822\" data-linked=\"YY +2% as Blue Lotus boosts to Buy\" data-tweet=\"$YY - YY +2% as Blue Lotus boosts to Buy https://seekingalpha.com/news/3385822-yyplus-2-blue-lotus-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3385822-yyplus-2-blue-lotus-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385820\" data-ts=\"1535375926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385820-premarket-gainers-of-9-05-08-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (08/27/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+18%</font>&nbsp;to <a href=\"https://seekingalpha.com/news/3385752-tilray-receive-initial-cannabis-order-nova-scotia-liquor-shares-6-percent-premarket\" target=\"_blank\">receive</a> cannabis order from Nova Scotia Liquor.</li>     <li><a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+15%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/NNDM' title='Nano Dimension Ltd ADR'>NNDM</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17253552-nano-dimension-sells-two-dragonfly-pro-3d-printers-u-s-armed-forces\" target=\"_blank\">selling</a> two DragonFly Pro 3D printers to US armed forces.</li>     <li><a href='https://seekingalpha.com/symbol/JMEI' title='Jumei International Holding Limited'>JMEI</a> <font color='green'>+13%</font>&nbsp;on 1H <a href=\"https://seekingalpha.com/news/3385692-jumei-reports-1h-results\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/AMWD' title='American Woodmark Corporation'>AMWD</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3385806-american-woodmark-plus-12-percent-buybacks-back\" target=\"_blank\">buyback</a>.</li>     <li><a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a> <font color='green'>+10%</font>&nbsp;on positive analyst <a href=\"https://seekingalpha.com/news/3385808-premarket-analyst-action-healthcare\" target=\"_blank\">action</a>.</li>     <li><a href='https://seekingalpha.com/symbol/NEPT' title='Neptune Wellness Solutions Inc.'>NEPT</a> <font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3385800-veru-lands-significant-south-africa-female-condom-tender\" target=\"_blank\">significant</a> South Africa female condom tender.</li>     <li><a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/EIGI' title='Endurance International Group Holdings, Inc.'>EIGI</a> <font color='green'>+7%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='green'>+7%</font>&nbsp;on positive analyst&nbsp;<a href=\"https://seekingalpha.com/news/3385808-premarket-analyst-action-healthcare\" target=\"_blank\">action</a></li>     <li><a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color='green'>+6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385820\" data-linked=\"Premarket Gainers as of 9:05 am (08/27/2018)\" data-tweet=\"$TLRY $TLRY $CRON - Premarket Gainers as of 9:05 am (08/27/2018) https://seekingalpha.com/news/3385820-premarket-gainers-of-9-05-08-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385820-premarket-gainers-of-9-05-08-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385811\" data-ts=\"1535375213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIDX\" target=\"_blank\">EIDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385811-premarket-losers-of-9-05-8-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (8/27/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/EIDX' title='Eidos Therapeutics'>EIDX</a> <font color='red'>-25%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385811\" data-linked=\"Premarket Losers as of 9:05 am (8/27/2018)\" data-tweet=\"$EIDX - Premarket Losers as of 9:05 am (8/27/2018) https://seekingalpha.com/news/3385811-premarket-losers-of-9-05-8-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3385811-premarket-losers-of-9-05-8-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385808\" data-ts=\"1535374900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385808-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) initiated with Neutral rating and $13 (25% upside) price target at BofA/Merrill Lynch citing challenges in driving omadacycline sales above $300M if it commercializes on its own.</li><li>Rigel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>) initiated with Buy rating and $8.50 (202% upside) at Citigroup citing expectations of $390M in peak sales for lead drug Tavalisse in ITP and 50% (coin toss) chance of success in autoimmune hemolytic anemia (mid-stage data expected in H1 2019). Shares up&nbsp;<font color='green'>11%</font>&nbsp;premarket on average volume.</li><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) upgraded to Neutral at Credit Suisse.</li><li>Medtronic (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) price target raised to $108 (13% upside) at Argus Research.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385808\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$PRTK $PRTK $RIGL - Premarket analyst action - healthcare https://seekingalpha.com/news/3385808-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3385808-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385806\" data-ts=\"1535374857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMWD\" target=\"_blank\">AMWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385806-american-woodmarkplus-12-buybacks-back-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Woodmark +12% with buybacks back on</a></h4><ul> <li>American Woodmark (NASDAQ:<a href='https://seekingalpha.com/symbol/AMWD' title='American Woodmark Corporation'>AMWD</a>) <font color='green'>jumps 12%</font> in premarket trading after topping Q1 profit estimates and drawing level on the revenue line.</li> <li>The company reported adjusted EBITDA of $68M for the quarter.</li> <li>Investors may be focused on the reinstatement of American Woodmark's stock repurchase program after a suspension in December of last year ahead of the RSI acquisition.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3385806\" data-linked=\"American Woodmark +12% with buybacks back on\" data-tweet=\"$AMWD - American Woodmark +12% with buybacks back on https://seekingalpha.com/news/3385806-american-woodmarkplus-12-buybacks-back-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3385806-american-woodmarkplus-12-buybacks-back-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385802\" data-ts=\"1535374360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESPR\" target=\"_blank\">ESPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385802-esperion-announces-positive-results-from-phase-3-bempedoic-acid-ezetimibe-combination-pill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Esperion announces positive results from phase 3 bempedoic acid / ezetimibe combination pill study</a></h4><ul> <li>Esperion (NASDAQ:<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a>) <a href=\"https://seekingalpha.com/pr/17253653-esperion-announces-positive-top-line-results-pivotal-phase-3-bempedoic-acid-ezetimibe\" target=\"_blank\">announces</a> positive top-line results from the pivotal Phase 3 bempedoic acid / ezetimibe combination pill study (1002-053). This trial was a randomized, double-blind study conducted to evaluate the efficacy and safety of the bempedoic acid 180 mg / ezetimibe 10 mg combination pill compared to bempedoic acid, ezetimibe or placebo in patients treated with maximally tolerated statins.</li>    <li>The study enrolling 382 high-risk patients met its key efficacy endpoints, including: 35% LDL-C lowering for the combination pill at 12 weeks compared to 3% for placebo, 24% for ezetimibe 10 mg &#40;EZE&#41; and 20% for bempedoic acid 180 mg &#40;BA&#41;;</li><li>Reduction of 34% for the FDC in high-sensitivity C-reactive protein (hsCRP) compared to 4% increase in placebo and 20% reductions for BA and 9% for EZE.</li><li>In a post-hoc analysis of patients considered statin intolerant, the combination pill LDL-C lowering was 43% compared to a 1% increase for placebo.</li>        <li>In this 12-week study, the bempedoic acid / ezetimibe combo pill was observed to be safe and well-tolerated.</li>  <li>Topline data from Study 2 (1002-047) are now expected in October. NDAs will be submitted during Q1 2019.</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3385802\" data-linked=\"Esperion announces positive results from phase 3 bempedoic acid / ezetimibe combination pill study\" data-tweet=\"$ESPR - Esperion announces positive results from phase 3 bempedoic acid / ezetimibe combination pill study https://seekingalpha.com/news/3385802-esperion-announces-positive-results-from-phase-3-bempedoic-acid-ezetimibe-combination-pill?source=tweet\" data-url=\"https://seekingalpha.com/news/3385802-esperion-announces-positive-results-from-phase-3-bempedoic-acid-ezetimibe-combination-pill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385800\" data-ts=\"1535374278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERU\" target=\"_blank\">VERU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385800-veru-lands-significant-south-africa-female-condom-tender\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veru lands significant South Africa female condom tender</a></h4><ul> <li>Veru (NASDAQ:<a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a>)&nbsp;announces that it landed 75% of a South Africa female condom tender.</li><li>The company says the overall tender is for up to 120M female condoms in total and orders may be placed under the award during the next three years.</li>  <li>\"The expected orders&rsquo; revenue from this tender award will help the continued development of Veru as a leading oncology and urology biopharmaceutical company,\" says CEO Mitchell Steiner.</li>  <li>VERU  <font color='green'>+5.91%</font> premarket to  $2.15.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17253783-veru-awarded-75-percent-south-africa-female-condom-tender\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3385800\" data-linked=\"Veru lands significant South Africa female condom tender\" data-tweet=\"$VERU - Veru lands significant South Africa female condom tender https://seekingalpha.com/news/3385800-veru-lands-significant-south-africa-female-condom-tender?source=tweet\" data-url=\"https://seekingalpha.com/news/3385800-veru-lands-significant-south-africa-female-condom-tender\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385795\" data-ts=\"1535373292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385795-tesla-sized-up-model-3-numbers-back-in-spotlight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla sized up with Model 3 numbers back in the spotlight</a></h4><ul> <li>It looks like we are back to VIN tracking on Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) after Elon Musk and the board agreed to keep the company in the public sphere.</li> <li>Baird analyst Ben Kallo is back on the offensive, saying Tesla has averaged about 1.5K VIN registrations per day in August. While conceding that Tesla's shares will remain under pressure as long as the SEC cloud hangs over it, he thinks investors may be underestimating the adjusting earnings potential of the EV automaker.</li> <li>In perhaps an important development, Tesla stated yesterday that it was not <a href=\"https://www.reuters.com/article/us-tesla-musk-stocks/tesla-shares-dip-3-percent-after-musk-abandons-buyout-idUSKCN1LC0CA\" target=\"_blank\">actively</a> searching to hire a chief operating officer. Many analysts have stated that a COO hire could soothe some anxiety around Tesla after the \"funding secured\" tweet, stories on Musk and the late Friday night timing of its stay public plan.</li> <li>Veteran Tesla watcher Gene Munster of Loup Ventures thinks it will take at least six months for the sound and fury around Tesla to fade away. \"This is not a situation where we can just forget about it. It&rsquo;s created a new layer of questions for investors. And now Tesla needs to get back to basics, which is ramping Model 3 production and profitability,\" Munster <a href=\"https://www.bloomberg.com/news/articles/2018-08-26/musk-s-brazen-gambit-collapsed-as-investor-support-withered\" target=\"_blank\">tells</a> Bloomberg.</li><li>Tesla is a little more than a month out from updating on Q3 production and deliveries.</li> <li>Shares of Tesla are <font color='red'>down 3.13%</font> in premarket trading to $312.70.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385701-tesla-stay-public\" target=\"_blank\">Tesla to stay public</a> (Aug. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385719-tesla-sinks-following-musk-reversal\" target=\"_blank\">Tesla sinks following Musk reversal</a> (Aug. 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3385795\" data-linked=\"Tesla sized up with Model 3 numbers back in the spotlight\" data-tweet=\"$TSLA - Tesla sized up with Model 3 numbers back in the spotlight https://seekingalpha.com/news/3385795-tesla-sized-up-model-3-numbers-back-in-spotlight?source=tweet\" data-url=\"https://seekingalpha.com/news/3385795-tesla-sized-up-model-3-numbers-back-in-spotlight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>136&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385792\" data-ts=\"1535372610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385792-amarin-set-to-announce-results-from-reduce-next-month-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin set to announce results from REDUCE-IT next month; shares up 1% premarket</a></h4><ul><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) <a href=\"https://seekingalpha.com/pr/17253519-amarin-s-reduce-clinical-study-now-positioned-next-large-cardiovascular-outcomes-study-report\" target=\"_blank\">announces </a>that topline results from its large-scale <a href=\"https://clinicaltrials.gov/ct2/show/NCT01492361?titles=reduce-it&amp;lead=amarin&amp;rank=1\" target=\"_blank\">REDUCE-IT</a> study assessing the cardiovascular effects of Vascepa (icosapent ethyl) should be released before the end of next month.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324386-amarin-almost-reduce-shares-28-percent-premarket\" target=\"_blank\">Amarin almost there with REDUCE-IT; shares up 28% premarket</a> (Jan. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385792\" data-linked=\"Amarin set to announce results from REDUCE-IT next month; shares up 1% premarket\" data-tweet=\"$AMRN - Amarin set to announce results from REDUCE-IT next month; shares up 1% premarket https://seekingalpha.com/news/3385792-amarin-set-to-announce-results-from-reduce-next-month-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3385792-amarin-set-to-announce-results-from-reduce-next-month-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385790\" data-ts=\"1535372496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRMR\" target=\"_blank\">BRMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385790-eclipse-resources-merging-blue-ride-mountain-resources-shares-down-nearly-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eclipse Resources merging with Blue Ride Mountain Resources; shares down nearly 8%</a></h4><ul><li>The all-stock deal will have Blue Ridge Mountain (<a href='https://seekingalpha.com/symbol/BRMR' title='Blue Ridge Mountain Resources, Inc.'>OTC:BRMR</a>) owners receiving 4.4259 shares of Eclipse (NYSE:<a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a>) for each share of BRMR they hold. Following the closing Eclipse will effect a 1:15 reverse stock split.</li><li>Based on Friday's close, it's a deal value of about $1.4B, with equity value of $908M.</li><li>About $15M in corporate synergies are seen.</li><li>Closing is expected in Q4.</li><li>A <a href=\"https://ir.eclipseresources.com/\" target=\"_blank\">conference call </a>is set for 10 ET.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17253610-b-eclipse-b-resources-corporation-blue-ridge-mountain-resources-inc-combine-stock-merger\" target=\"_blank\">Press Release</a></li><li>Eclipse&nbsp;<font color='red'>down 7.75%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3385790\" data-linked=\"Eclipse Resources merging with Blue Ride Mountain Resources; shares down nearly 8%\" data-tweet=\"$BRMR $BRMR $ECR-OLD - Eclipse Resources merging with Blue Ride Mountain Resources; shares down nearly 8% https://seekingalpha.com/news/3385790-eclipse-resources-merging-blue-ride-mountain-resources-shares-down-nearly-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3385790-eclipse-resources-merging-blue-ride-mountain-resources-shares-down-nearly-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385772\" data-ts=\"1535370818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385772-advanced-micro-up-3_5-on-new-graphics-card\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advanced Micro up 3.5% on new graphics card</a></h4><ul><li>The company over the weekend introduced its Radeon Pro V340 graphics card. It's expected to be available in Q4.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17253517-new-b-amd-b-radeon-pro-v340-graphics-card-delivers-accelerated-performance-high-user-density\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>&nbsp;<font color='green'>+3.5%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3385772\" data-linked=\"Advanced Micro up 3.5% on new graphics card\" data-tweet=\"$AMD - Advanced Micro up 3.5% on new graphics card https://seekingalpha.com/news/3385772-advanced-micro-up-3_5-on-new-graphics-card?source=tweet\" data-url=\"https://seekingalpha.com/news/3385772-advanced-micro-up-3_5-on-new-graphics-card\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>296&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385761\" data-ts=\"1535369750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385761-u-s-steel-down-nearly-3-morgan-stanley-bails-steel-dynamics-ak-steel-upgraded\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Steel down nearly 3% as Morgan Stanley bails; Steel Dynamics, AK Steel upgraded</a></h4><ul><li>Analyst&nbsp;Piyush Sood delivers a two-notch downgrade to U.S. Steeel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>), cutting to Underweight from Overweight, with price target trimmed to $30 from $44.</li><li>Shares continue their summer slump,&nbsp;<font color='red'>down 2.8%</font>&nbsp;premarket to $30.09.</li><li>Alongside, Sood upgrades Steel Dynamics (NASDAQ:<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a>) to Overweight from Equalweight. The new $52 price target suggests&nbsp;<font color='green'>16% upside</font>&nbsp;from Friday. Shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $45.30.</li><li>AK Steel (NYSE:<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a>) is also boosted to Overweight, with $5.50 price target suggesting&nbsp;<font color='green'>nearly 30% upside</font>. Shares are&nbsp;<font color='green'>up 3.5%</font>&nbsp;premarket to $4.44.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385761\" data-linked=\"U.S. Steel down nearly 3% as Morgan Stanley bails; Steel Dynamics, AK Steel upgraded\" data-tweet=\"$X $X $STLD - U.S. Steel down nearly 3% as Morgan Stanley bails; Steel Dynamics, AK Steel upgraded https://seekingalpha.com/news/3385761-u-s-steel-down-nearly-3-morgan-stanley-bails-steel-dynamics-ak-steel-upgraded?source=tweet\" data-url=\"https://seekingalpha.com/news/3385761-u-s-steel-down-nearly-3-morgan-stanley-bails-steel-dynamics-ak-steel-upgraded\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385759\" data-ts=\"1535369528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385759-pfizers-tafamidis-shows-positive-effect-in-late-stage-attr-cm-study-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfizer&#39;s tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket</a></h4><ul><li>Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17253580-tafamidis-phase-3-transthyretin-amyloid-cardiomyopathy-attr-act-study-results-presented-late\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02791230?term=NCT02791230&amp;rank=1\" target=\"_blank\">ATTR-ACT</a>, evaluating Vyndaqel (tafamidis) in patients with a rare disorder called wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy (ATTR-CM).</li><li>Patients with ATTR-CM receiving tafamidis experienced less all-cause mortality and frequency of cardiovascular &#40;CV&#41;-related hospitalizations versus placebo over a 30-month treatment period.</li><li>Specifically, patients in the treatment group experienced all-cause mortality of 29.5% compared to 42.9% for control (hazard ratio = 0.70; p=0.0259) and a 0.48 annualized rate of CV-related hospitalization versus 0.70 for control (relative risk ratio = 0.68; p&lt;0.0001).</li><li>Tafamidis-treated patients also showed reduced declines in six-minute walk test distance (p&lt;0.0001) and reduced declines in quality of life measures (p&lt;0.0001).</li><li>The data were presented at the ESC Congress in Munich and published online in the <em>New England Journal of Medicine</em>.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>2%</font>&nbsp;in early trade as investors see headwinds facing tafamidis from Alnlyam's patisiran and Akcea's inotersen.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385759\" data-linked=\"Pfizer&#39;s tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket\" data-tweet=\"$PFE - Pfizer&#39;s tafamidis shows positive effect in late-stage ATTR-CM study; shares up 1% premarket https://seekingalpha.com/news/3385759-pfizers-tafamidis-shows-positive-effect-in-late-stage-attr-cm-study-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3385759-pfizers-tafamidis-shows-positive-effect-in-late-stage-attr-cm-study-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385752\" data-ts=\"1535368163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385752-tilray-to-receive-initial-cannabis-order-from-nova-scotia-liquor-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray to receive initial cannabis order from Nova Scotia Liquor; shares up 6% premarket</a></h4><ul><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17253629-tilray-selected-nova-scotia-liquor-corporation-supply-variety-adult-use-cannabis-brands\" target=\"_blank\">announcement </a>that Nova Scotia Liquor has selected it for an initial cannabis order ahead of Canada's launch of the adult-use market on October 17.</li><li>The company will fulfill the order through affiliate High Park Holdings Ltd., doing business as High Park Company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3385752\" data-linked=\"Tilray to receive initial cannabis order from Nova Scotia Liquor; shares up 6% premarket\" data-tweet=\"$TLRY - Tilray to receive initial cannabis order from Nova Scotia Liquor; shares up 6% premarket https://seekingalpha.com/news/3385752-tilray-to-receive-initial-cannabis-order-from-nova-scotia-liquor-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3385752-tilray-to-receive-initial-cannabis-order-from-nova-scotia-liquor-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3385719\" data-ts=\"1535358347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3385719-tesla-sinks-following-musk-reversal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla sinks following Musk reversal</a></h4><ul><li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) <font color='red'>-5.4%</font> premarket after Elon Musk called off his $72B bid to take the company private.</li><li>The decision to scuttle the proposed deal was motivated in part by existing Tesla shareholders who said they wanted the luxury EV maker to remain publicly-traded.</li><li>Other concerns centered on ceding too much control to private investors and shutting out smaller investors who might be unable to retain a stake.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385701-tesla-stay-public\" target=\"_blank\">Tesla to stay public</a> (Aug. 24 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3385719\" data-linked=\"Tesla sinks following Musk reversal\" data-tweet=\"$TSLA - Tesla sinks following Musk reversal https://seekingalpha.com/news/3385719-tesla-sinks-following-musk-reversal?source=tweet\" data-url=\"https://seekingalpha.com/news/3385719-tesla-sinks-following-musk-reversal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>203&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":70,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}